Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA

Chang, Rae Sung; Suh, Min Sung; Kim, Sunil; Shim, Gayong; Lee, Sangbin; Han, Sung Sik; Lee, Jun Young; Jeon, Hyesung; Choi, Han Gon; Choi, Yongseok; Kim, Chan Wha; Oh, Yu‐Kyoung

doi:10.1016/j.biomaterials.2011.09.017

Cited by 64 publications

(40 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the co-delivery can be achieved by conjugating the drug or the siRNA to the liposome. Chang et al conjugated small molecule anticancer drug mitoxantrone (MTO) with palmitoleic acid to form monopalmitoleyl MTO (mono-Pal-MTO) or dipalmitoleyl MTO (di-Pal-MTP) prodrugs and used the cationic prodrugs as building blocks to form multilayered cationic liposome (md11-Pal-MTO) for the co-delivery of MTO and MCL1 siRNA (siMCL1) [64]. The size of liposomes after siRNA complexation is around 200 nm measured by dynamic light scattering (DLS).…”

Section: Lipid-based Nanocarriers Liposomesmentioning

confidence: 99%

“…MCL1 siRNA Multilayered prodrug cationic liposome -In vivo test on KB epidermal carcinoma xenograft mice model by intratumoral injection for 3 days showed that 17 days after the last day of injection, the codelivery liposomes completely suppressed tumor growth, in comparison, the tumors grew to five-times and six-times of their original volumes after being treated with MTO-loaded liposomes and free MTO, respectively [64] Camptothecin (CPT) and…”

Section: Vapreotidementioning

confidence: 99%

See 1 more Smart Citation

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Zhao

Feng

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

A major problem in cancer treatment is the multidrug resistance. siRNA inhibitors have great advantages to solve the problem, if the bottleneck of their delivery could be well addressed by the various nanocarriers. Moreover, co-delivery of siRNA together with the various anticancer agents in one nanocarrier may maximize their additive or synergistic effect. This review provides a comprehensive summary on the state-of-the-art of the nanocarriers, which may include prodrugs, micelles, liposomes, dendrimers, nanohydrogels, solid lipid nanoparticles, nanoparticles of biodegradable polymers and nucleic acid nanocarriers for delivery of siRNA and co-delivery of siRNA together with anticancer agents with focus on synthesis of the nanocarrier materials, design and characterization, in vitro and in vivo evaluation, and prospect and challenges of nanocarriers.

show abstract

Section: Lipid-based Nanocarriers Liposomesmentioning

confidence: 99%

Section: Vapreotidementioning

confidence: 99%

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Zhao

Feng

2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…As a result, combination therapy (drugs, proteins, or oligonucleotides) in a single nanodelivery system holds great potential due to selective accumulation at tumor site to give synergistic effects of different therapeutic agents. Sufficient research is available on combination drug therapies for cancer using nanocarriers, but limited data are available on delivery of drug-nucleic acid combination (Eldar-boock et al 2013;Hou et al 2011) Co-delivery approaches, wherein nucleic acids and anticancer drug are entrapped in the same multifunctional nanocarrier to achieve the synergistic effect of gene therapy with chemotherapy have recently drawn attention (Chang et al 2011;Li et al 2013a, b). At the same time, loading and simultaneous delivery of small and macromolecule by tumor-targeted nanocarriers are a very challenging task due to vast difference in their physicochemical characteristics.…”

Section: Introductionmentioning

confidence: 98%

Self-assembled nanocomplexes of anionic pullulan and polyallylamine for DNA and pH-sensitive intracellular drug delivery

et al. 2014

View full text Add to dashboard Cite

The amalgamation of chemotherapy and gene therapy is promising treatment option for cancer. In this study, novel biocompatible self-assembled nanocomplexes (NCs) between carboxylmethylated pullulan t335 (CMP) with polyallylamine (CMP-PAA NCs) were developed for plasmid DNA (pDNA) and pH-sensitive doxorubicin (DOX) delivery. DOX was conjugated to CMP (DOX-CMP) via hydrazone and confirmed by FTIR and 1 H-NMR. In vitro release studies of pH-sensitive DOX-CMP conjugate showed 23 and 85 % release after 48 h at pH 7.4 (physiological pH) and pH 5 (intracellular/tumoral pH), respectively. The CMP-PAA NCs or DOX-CMP-PAA NCs self-assembled into a nanosized (\250 nm) spherical shape as confirmed by DLS and TEM. The hemolysis and cytotoxicity study indicated that the CMP-PAA NCs did not show cytotoxicity in comparison with plain polyallylamine. Gel retardation assay showed complete binding of pDNA with CMP-PAA NCs at 1:2 weight ratio. CMP-PAA NCs/pDNA showed significantly higher transfection in HEK293 cells compared to PAA/pDNA complexes. Confocal imaging demonstrated successful cellular uptake of DOX-CMP-PAA NCs in HEK293 cells. Thus, NCs hold great potential for targeted pDNA and pH-sensitive intratumoral drug delivery.

show abstract

“…Recently, the efforts of many research groups have focused on development of new genetic drugs in order to improve their effectiveness and specificity, and to provide the possibility of full control of their action. Molecules such as antisense oligonucleotides 7 or small inhibitory RNAs can be used to inhibit particular gene expression as sole therapeutics or in combination with other therapeutic approaches, to enhance the effectiveness of non-gene therapy (e.g., with cytostatic agents and/or radiation treatment for cancer diseases 8 ). As nucleic acid molecules are rather poorly internalized by cells, various carriers have been developed, of which the viral-derived vectors proved the most effective although the least safe.…”

Section: Introductionmentioning

confidence: 99%

Liposome-coated lipoplex–based carrier for antisense oligonucleotides

Wyrozumska

Meissner

Toporkiewicz

et al. 2014

Cancer Biology & Therapy

View full text Add to dashboard Cite

fluorescent protein; HPC, hydrogenated egg phosphatidylcholine); pDNA, plasmid DNA; PE/PC, phosphatidylethanolamine and phosphatidylcholine liposomes; siRNA, small interferingRNA TGI, tumor growth inhibition.The chemical nature of genetic drugs (e.g. antisense oligonucleotides, siRNA, vectors) requires a suitable carrier system to protect them from enzymatic degradation without changing their properties and enable efficient delivery into target cells. Lipid vectors for nucleic acid delivery that have been widely investigated for years can be very effective. As the majority of attempts made in the field of cancer gene therapy have focused on solid tumors, while blood cancer cells have attracted less attention, the latter became the subject of our investigation. The lipid carrier proposed here is based on liposomes constructed by others but the lipid composition is original. A liposome-coated lipoplex (L-cL) consists of a core arising from complexation of positively charged lipid and negatively charged oligodeoxynucleotide (ODN) or plasmid DNA coated by a neutral or anionic lipid bilayer. Moreover, our lipid vector demonstrates size stability and is able to retain a high content of enclosed plasmid DNA or antisense oligodeoxynucleotides (asODNs). Observed transfection efficacies of the tested preparation using a plasmid coding for fluorescent protein were up to 60-85% of examined leukemia cells (Jurkat T and HL-60 lines) in the absence or the presence of serum. When BCL-2 asODN was encapsulated in the L-cL, specific silencing of this gene product at both the mRNA and protein level and also a markedly decreased cell survival rate were observed in vitro. Moreover, biodistribution analysis in mice indicates prolonged circulation characteristic for PEG-modified liposomal carriers. Experiments on tumor-engrafted animals indicate substantial inhibition of tumor growth.

show abstract

Cationic drug-derived nanoparticles for multifunctional delivery of anticancer siRNA

Cited by 64 publications

References 33 publications

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Nanocarriers for Delivery of siRNA and Co-Delivery of siRNA and Other Therapeutic Agents

Self-assembled nanocomplexes of anionic pullulan and polyallylamine for DNA and pH-sensitive intracellular drug delivery

Liposome-coated lipoplex–based carrier for antisense oligonucleotides

Contact Info

Product

Resources

About